Studying platelet markers to help diagnose ALS
Looks for platelet markers that may help tell ALS apart from other motor neuron diseases.
Plain-language title generated from the registry record
Registry title: Characterization of Platelet Molecular Profiles in ALS for the Identification of Specific Diagnostic Biomarkers - A Pilot Study
Key facts
- Where
- Limoges, Lyon, and Tours, FranceSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07479017, who can take part
Where in France
- University Hospital, LimogesLimoges, FranceNo longer taking part
- University hospital, LyonLyon, FranceNo longer taking part
- university hospital, ToursTours, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Tours
- Trial code
- NCT07479017
- Record updated
- 18 March 2026
- Original description
The search for diagnostic biomarkers that can be used routinely is a major challenge to manage Amyotrophic lateral sclerosis (ALS) in order to characterize the pathophysiology and accelerate the management of the disease. Some non-specific biomarkers have been proposed (Neurofilaments, TDP-43) but their diagnostic value remains controversial. This study aims to identify ALS-specific platelet biomarkers using targeted and untargeted multi-omic approaches, in order to enable differential diagnosis between ALS and other motor neuron diseases.Read full original descriptionShow less
Characterization of Platelet Molecular Profiles in ALS for the Identification of Specific Diagnostic Biomarkers - A Pilot Study
The search for diagnostic biomarkers that can be used routinely is a major challenge to manage Amyotrophic lateral sclerosis (ALS) in order to characterize the pathophysiology and accelerate the management of the disease. Some non-specific biomarkers have been proposed (Neurofilaments, TDP-43) but their diagnostic value remains controversial. This study aims to identify ALS-specific platelet biomarkers using targeted and untargeted multi-omic approaches, in order to enable differential diagnosis between ALS and other motor neuron diseases.
Inclusion: Patients with ALS:; Men or women aged 18 to 75; ALS diagnosed according to the El Escorial criteria; ALS diagnosis less than 3 months ago; Onset of symptoms defined as the time when muscle weakness was first observed by the patient less than 2 years ago; Controls with another motor neuron disease:; Men or women aged 18 to 75; Diagnosis of motor neuron disease < 3 months.
Exclusion: Treatment with oral or injectable anticoagulants, antiplatelet agents (EXCEPT aspirin at the maximum authorized dosage of 160 mg per day); Uncontrolled diabetes; Genetic variants associated with ALS; Pregnant or breastfeeding women; Persons deprived of their liberty by judicial or administrative decision; Persons subject to legal protection measures: guardianship or curatorship; Opposition to data processing.